Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102131034 | 10213103 | 4 | F | 20140316 | 20160601 | 20140603 | 20160927 | EXP | CA-BEH-2014042600 | CSL BEHRING | 78.00 | YR | E | F | Y | 90.00000 | KG | 20160927 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102131034 | 10213103 | 1 | PS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 26 ML/HR TO 200 ML/HR; FOR 3 DAYS | 4336400018 | 125201 | 90 | G | INFUSION | ||||||
| 102131034 | 10213103 | 2 | SS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 4353100051 | 125201 | 90 | G | INFUSION | |||||||
| 102131034 | 10213103 | 3 | SS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 4353100050 | 125201 | 90 | G | INFUSION | |||||||
| 102131034 | 10213103 | 4 | SS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 4366600003 | 125201 | 90 | G | INFUSION | |||||||
| 102131034 | 10213103 | 5 | SS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 4370800005 | 125201 | 90 | G | INFUSION | |||||||
| 102131034 | 10213103 | 6 | SS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 4370800008 | 125201 | 90 | G | INFUSION | |||||||
| 102131034 | 10213103 | 7 | SS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 26 ML/HR TO 200 ML/HR; FOR 3 DAYS | 125201 | 90 | G | INFUSION | QD | ||||||
| 102131034 | 10213103 | 8 | SS | PRIVIGEN | HUMAN IMMUNOGLOBULIN G | 1 | Intravenous (not otherwise specified) | 26 ML/HR TO 200 ML/HR; FOR 3 DAYS | 125201 | 90 | G | INFUSION | QD | ||||||
| 102131034 | 10213103 | 9 | SS | Packed red blood cells | HUMAN RED BLOOD CELL | 1 | 0 | ||||||||||||
| 102131034 | 10213103 | 10 | SS | Packed red blood cells | HUMAN RED BLOOD CELL | 1 | 0 | ||||||||||||
| 102131034 | 10213103 | 11 | SS | Packed red blood cells | HUMAN RED BLOOD CELL | 1 | 0 | ||||||||||||
| 102131034 | 10213103 | 12 | SS | PLATELETS | HUMAN PLATELET, ALLOGENIC | 1 | 0 | ||||||||||||
| 102131034 | 10213103 | 13 | SS | PLATELETS | HUMAN PLATELET, ALLOGENIC | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 102131034 | 10213103 | 1 | Immune thrombocytopenic purpura |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 102131034 | 10213103 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 102131034 | 10213103 | Haemolysis | |
| 102131034 | 10213103 | Pulmonary embolism |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 102131034 | 10213103 | 7 | 20140307 | 20140310 | 0 | |
| 102131034 | 10213103 | 8 | 20140317 | 20140319 | 0 | |
| 102131034 | 10213103 | 9 | 20140308 | 20140308 | 0 | |
| 102131034 | 10213103 | 10 | 20140309 | 20140309 | 0 | |
| 102131034 | 10213103 | 11 | 20140309 | 20140309 | 0 | |
| 102131034 | 10213103 | 12 | 20140307 | 20140307 | 0 | |
| 102131034 | 10213103 | 13 | 20140315 | 20140315 | 0 |